Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$144.35−0.25 (-0.17%)
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Palvella Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Palvella Therapeutics's ebitda for the twelve months ending Sep 30, 2024 was $3.43M. For fiscal 2023 it was -$9.97M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$9.97M | – |
| FY2022 | Dec 31, 2022 | -$40.70M | – |
| FY2021 | Dec 31, 2021 | -$49.37M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -$5.06M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.91M | -203.1% |
| Q1 FY2024 | Mar 31, 2024 | -$1.79M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.07M | – |
| Q2 FY2023 | Jun 30, 2023 | $2.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.39M | – |
See a number that looks wrong?